Novo Nordisk makes $1.1bn bid for biopharma company

02-09-2022

Staff Writer

Novo Nordisk makes $1.1bn bid for biopharma company

JHVEPhoto / Shutterstock.com

Massachusetts-based target company specialises in rare blood disorders | Deal gives Novo Nordisk access to lead development candidate, etavopivat.


Novo Nordisk, Forma Therapeutics, M&A, mergers and acquisitions, sickle cell disease, Etavopivat

LSIPR